We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects
Read MoreHide Full Article
Did you analyze how Insmed (INSM - Free Report) fared in its international operations for the quarter ending March 2025? Given the widespread global presence of this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.
In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.
Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.
In our recent assessment of INSM's quarterly performance, we discovered notable trends in its overseas revenue sections, which are typically modeled and scrutinized by Wall Street analysts.
The company's total revenue for the quarter amounted to $92.82 million, showing rise of 22.9%. We will now explore the breakdown of INSM's overseas revenue to assess the impact of its international operations.
A Look into INSM's International Revenue Streams
Of the total revenue, $22.1 million came from Japan during the last fiscal quarter, accounting for 23.81%. This represented a surprise of -20.93% as analysts had expected the region to contribute $27.95 million to the total revenue. In comparison, the region contributed $30.7 million, or 29.39%, and $14.89 million, or 19.72%, to total revenue in the previous and year-ago quarters, respectively.
Europe and rest of world accounted for 7.00% of the company's total revenue during the quarter, translating to $6.5 million. Revenues from this region represented a surprise of +14.44%, with Wall Street analysts collectively expecting $5.68 million. When compared to the preceding quarter and the same quarter in the previous year, Europe and rest of world contributed $5.9 million (5.65%) and $4.26 million (5.64%) to the total revenue, respectively.
Revenue Forecasts for the International Markets
For the current fiscal quarter, it is anticipated by Wall Street analysts that Insmed will report a total revenue of $102.43 million, which reflects an increase of 13.4% from the same quarter in the previous year. The revenue contributions are expected to be 28.7% from Japan ($29.4 million) and 5.7% from Europe and rest of world ($5.81 million).
For the full year, the company is projected to achieve a total revenue of $463.74 million, which signifies a rise of 27.5% from the last year. The share of this revenue from various regions is expected to be: Japan at 26.4% ($122.45 million) and Europe and rest of world at 5% ($23.33 million).
Closing Remarks
Relying on global markets for revenues presents both prospects and challenges for Insmed. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
Over the past month, the stock has seen a decline of 4.6% in its value, whereas the Zacks S&P 500 composite has posted an increase of 9.1%. The Zacks Medical sector, Insmed's industry group, has ascended 1.4% over the identical span. In the past three months, there's been a decline of 14.6% in the company's stock price, against a fall of 3.1% in the S&P 500 index. The broader sector has declined by 8.7% during this interval.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects
Did you analyze how Insmed (INSM - Free Report) fared in its international operations for the quarter ending March 2025? Given the widespread global presence of this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.
In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.
Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.
In our recent assessment of INSM's quarterly performance, we discovered notable trends in its overseas revenue sections, which are typically modeled and scrutinized by Wall Street analysts.
The company's total revenue for the quarter amounted to $92.82 million, showing rise of 22.9%. We will now explore the breakdown of INSM's overseas revenue to assess the impact of its international operations.
A Look into INSM's International Revenue Streams
Of the total revenue, $22.1 million came from Japan during the last fiscal quarter, accounting for 23.81%. This represented a surprise of -20.93% as analysts had expected the region to contribute $27.95 million to the total revenue. In comparison, the region contributed $30.7 million, or 29.39%, and $14.89 million, or 19.72%, to total revenue in the previous and year-ago quarters, respectively.
Europe and rest of world accounted for 7.00% of the company's total revenue during the quarter, translating to $6.5 million. Revenues from this region represented a surprise of +14.44%, with Wall Street analysts collectively expecting $5.68 million. When compared to the preceding quarter and the same quarter in the previous year, Europe and rest of world contributed $5.9 million (5.65%) and $4.26 million (5.64%) to the total revenue, respectively.
Revenue Forecasts for the International Markets
For the current fiscal quarter, it is anticipated by Wall Street analysts that Insmed will report a total revenue of $102.43 million, which reflects an increase of 13.4% from the same quarter in the previous year. The revenue contributions are expected to be 28.7% from Japan ($29.4 million) and 5.7% from Europe and rest of world ($5.81 million).For the full year, the company is projected to achieve a total revenue of $463.74 million, which signifies a rise of 27.5% from the last year. The share of this revenue from various regions is expected to be: Japan at 26.4% ($122.45 million) and Europe and rest of world at 5% ($23.33 million).
Closing Remarks
Relying on global markets for revenues presents both prospects and challenges for Insmed. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
At the moment, Insmed has a Zacks Rank #3 (Hold), signifying that its performance may align with the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Insmed's Recent Stock Market Performance
Over the past month, the stock has seen a decline of 4.6% in its value, whereas the Zacks S&P 500 composite has posted an increase of 9.1%. The Zacks Medical sector, Insmed's industry group, has ascended 1.4% over the identical span. In the past three months, there's been a decline of 14.6% in the company's stock price, against a fall of 3.1% in the S&P 500 index. The broader sector has declined by 8.7% during this interval.